Pentagalloylglucose down-regulates mast cell surface FcεRI expression in vitro and in vivo  by Kageyama-Yahara, Natsuko et al.
FEBS Letters 584 (2010) 111–118journal homepage: www.FEBSLetters .orgPentagalloylglucose down-regulates mast cell surface FceRI expression in vitro
and in vivo
Natsuko Kageyama-Yahara a,*, Yoko Suehiro a, Futoshi Maeda a, Shun-ichiro Kageyama b, Junya Fukuoka b,
Tatsuo Katagiri c, Takeshi Yamamoto a, Makoto Kadowaki a
aDivision of Gastrointestinal Pathophysiology, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan
b The Laboratory of Pathology, Toyama University Hospital, Toyama, Japan
cDepartment of Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
a r t i c l e i n f o a b s t r a c tArticle history:
Received 3 July 2009
Revised 30 October 2009
Accepted 3 November 2009
Available online 11 November 2009
Edited by Beat Imhof
Keywords:
Mast cell
Gene expression
Allergy0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.11.007
Abbreviations: BSA, bovine serum albumin; DNP
afﬁnity IgE receptors; GA, gallic acid; IgE, immunoglob
lamina propria mononuclear cell; mBMMC, mucosal
derived mast cell; mMCP-1, mouse mast cell protea
1,2,3,4,6-penta-O-galloyl-b-D-glucose; TGF-b1, transfor
1,3,6-tri-O-galloyl-b-D-glucose
* Corresponding author. Address: Division of Gast
Department of Bioscience, Institute of Natural Med
2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan.
E-mail address: natsuko@inm.u-toyama.ac.jp (N. KMast cell activation by immunoglobulin E (IgE)-mediated stimuli is a central event in the pathogen-
esis of allergic disorders. The present report shows that treatment with pentagalloylglucose (PGG)
resulted in a down-regulation of FceRI surface expression on mucosal-type murine bone marrow-
derived mast cells (mBMMCs), which correlated with a reduction in IgE-mediated activation of
mBMMCs. Furthermore, PGG prevented development of allergic diarrhea in a food-allergy mouse
model and suppressed the up-regulated FceRI surface expression on mast cells derived from the
food-allergy mouse colon. These ﬁndings on PGG suggest its therapeutic potential for allergic dis-
eases through suppressing the FceRI surface expression.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Allergic diseases are characterized by increases in the number
of mast cells and the plasma level of immunoglobulin E (IgE) anti-
bodies that signal through high-afﬁnity IgE receptors (FceRI) to in-
duce the release of inﬂammatory mediators from mast cells. There
are two distinct populations of mast cells, namely, mucosal mast
cells and connective-tissue mast cells. So far, there has been con-
siderable evidence demonstrating that mucosal mast cells are mor-
phologically, biochemically, and functionally distinct from
connective-tissue mast cells [1–4].
We found that the number of mucosal mast cells was greatly in-
creased in the colons of the food-allergy model mice [5]. It is now
clear that the mast cell’s functional responses to IgE-dependent
stimulation can be greatly inﬂuenced by the level of expression
of FceRI on the cell surface. It was reported that IgE can potentlychemical Societies. Published by E
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ageyama-Yahara).enhance the FceRI surface expression of mast cells and show en-
hanced sensitivity and a stronger response to antigenic stimulation
[6]. On the other hand, interleukin (IL)-4, IL-10, and transforming
growth factor-b1 (TGF-b1) have been shown to down-regulate
FceRI expression and thereby inhibit IgE-mediated cytokine pro-
duction in mast cells [7].
Previously, we found that Kakkonto, a traditional Japanese her-
bal medicine, signiﬁcantly suppressed the occurrence of allergic
diarrhea in the food-allergy model mice [5]. Because mucosal mast
cells play an important role in the development of food-allergy
symptoms [8], it was hypothesized that Kakkonto may have a di-
rect effect on mucosal mast cells. The present study investigated
the effect of Kakkonto and its components on mBMMCs. Our re-
sults demonstrate that 1,2,3,4,6-penta-O-galloyl-b-D-glucose (pen-
tagalloylglucose, PGG), a constituent of Kakkonto, suppressed mast
cells function through down-regulating the FceRI surface expres-
sion both in vitro and in vivo.2. Materials and methods
2.1. Cell culture and degranulation assay
mBMMCs were prepared from BALB/c mice according to the
method described previously [9,10]. Rat basophilic leukemia
(RBL)-1 cells were provided by Health Science Research Resourceslsevier B.V. All rights reserved.
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Fig. 1. Kakkonto and Paeoniae Radix inhibit mBMMC degranulation and down-regulates surface expression of high-afﬁnity IgE receptors (FceRI). (A) mBMMCs were sensitized
with immunoglobulin E (IgE) anti-dinitrophenyl (DNP), and activated by DNP-bovine serum albumin (BSA). Kakkonto at the concentrations noted was added during pre-
incubation (24 h) and sensitization (6 h), stimulated with DNP-BSA for 1 h, and b-hexosaminidase release was determined. Data represent mean ± S.D. values of three
experiments. *P < 0.05 compared to vehicle-treated cells. (B) mBMMCs were cultured with Kakkonto (2 mg/mL) for 24 h, and surface expression levels of FceRIa (ﬁlled) and c-
kit (gray) were determined by ﬂow cytometry. Data represent mean ± S.D. values of four experiments. **P < 0.01 compared to vehicle-treated cells. (C) Paeoniae Radix extracts
at the concentrations noted were added during pre-incubation and sensitization. The treated cells were stimulated with (ﬁlled) or without (open) DNP-BSA for 1 h, and b-
hexosaminidase release was determined. Data represent mean ± S.D. values of three experiments. *P < 0.05 compared with vehicle-treated cells. (D) mBMMCs were cultured
with Paeoniae Radix (2 mg/mL) extracts for 24 h, and the surface expression levels of FceRIa (ﬁlled) and c-kit (gray) were determined by ﬂow cytometry. Data represent
mean ± S.D. values of three experiments. **P < 0.01 compared to vehicle-treated cells.
Table 1
Medicinal plant compositions of various Japanese herbal medicines.
Kakkonto (%) Keishito (%) Syomakakkonto (%) Syakuyakukanzoto (%) Hochuekkito (%) Shikunshito (%)
Paeoniae Radix 11 26 25 50
Glycyrrhizae Radix 11 13 13 50 6 7
Puerariae Radix 22 42
Zizyphi Fructus 17 26 8 7
Ephedrae Herba 17
Cinnamomi Cortex 11 26
Zingiberis Rhizoma 11 10 4 2 7
Cimicifugae Rhizoma 17 4
Bupleuri Radix 8
Atractylodis Lanceae Rhizoma 17 27
Ginseng Radix 17 27
Poria 27
Astragali Radix 17
Angelicae Radix 13
Aurantii Nobilis 8
b-Hexosaminidase release (%) 15.7 ±4.9** 14.1 ±4.4** 15.0 ± 8.7** 24.2 ± 17.4** 68.8 ± 8.7 66.7 ± 10.4
Data of b-hexosaminidase release represent mean ± SD values of three experiments.
** P < 0.01 compared with vehicle-treated cells.
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Fig. 2. 1,2,3,4,6-Penta-O-galloyl-b-D-glucose (PGG) inhibits mBMMC degranulation and down-regulates surface expression of FceRI. (A) mBMMCs were incubated with
100 lM of PGG, paeoniﬂorin, albiﬂorin, oxypaeoniﬂorin, paeonol and vehicle for 24 h, and the surface expression levels of FceRI were determined by ﬂow cytometry. (B)
mBMMCs were incubated with PGG at the concentrations noted for 24 h, and the surface expression levels of FceRI and c-kit were determined by ﬂow cytometry. Data
represent mean ± S.D. values of 4 experiments. *P < 0.05 compared with vehicle-treated cells. (C) PGG at the concentrations noted was added during pre-incubation (24 h) and
sensitization (6 h). The treated cells were stimulated with (ﬁlled) or without (open) DNP-BSA for 1 h, and b-hexosaminidase release was determined. Data represent
mean ± S.D. values of four experiments. *P < 0.05 compared with vehicle-treated cells. (D) RBL-1 and RBL-2H3 cells were treated with 100 lM PGG and vehicle for 24 h and
surface expression levels of FceRI were determined by ﬂow cytometry. Data represent mean ± S.D. values of four experiments. *P < 0.05 compared with vehicle-treated cells.
(E) mBMMCs were incubated with 100 lM PGG or vehicle for 24 h, and the cells were stimulated with (ﬁlled) or without (open) 1 lM calcium ionophore A23187 for 20 min.
Release of b-hexosaminidase was determined. Data represent mean ± S.D. values of three experiments.
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kindly provided by Dr. Hidetaka Yakura (Tokyo Metropolitan Insti-
tute for Neuroscience, Tokyo, Japan).
The degree of degranulation was assessed by measuring b-hex-
osaminidase release as previously described [10].2.2. Flow cytometry analysis
mBMMCs were washed with FACS buffer (PBS, 1% bovine
serum albumin (BSA), 0.2% NaN3), stained with FITC-labeled anti-
mouse FceRI alpha (clone MAR-1, eBioscience, San Diego, CA) and
*+ 32 μM PGG
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Fig. 3. (A) Tranilast, ketotifen, and cromolyn (10 lM each) were added to mBMMCs 30 min before being activated by the antigen DNP-BSA, and the extent of degranulation
was assessed. The cells treated with vehicle or 100 lM PGG during pre-incubation (24 h) and sensitization (6 h) were used as controls. Data represent mean ± S.D. values of
three experiments. *P < 0.05 compared with vehicle-treated cells. (B and C) Effects of 1,3,6-tri-O-galloyl-b-D-glucose (TGG) and gallic acid (GA) on the surface expression levels
of FceRI (B) and degranulation (C). mBMMCs were treated with 100 lM PGG, TGG, GA and vehicle for 24 h, and surface expressions of FceRI were determined by ﬂow
cytometry (B). After pre-incubation and sensitization, the treated cells were stimulated with (ﬁlled) or without (open) DNP-BSA for 1 h, and b-hexosaminidase release was
determined (C). Data represent mean ± S.D. values of three experiments. *P < 0.05 compared with vehicle-treated cells. (D) Ca2+-mobilization proﬁles, monitored by Fura-2
AM. mBMMCs were treated with 32 lM PGG or vehicle (control), sensitized with IgE, and labeled with Fura-2 AM. Ca2+-mobilization was determined after stimulation with
DNP-BSA. Results shown are representative of four separate experiments.
114 N. Kageyama-Yahara et al. / FEBS Letters 584 (2010) 111–118PE-labeled anti-mouse CD117 (c-kit) (clone ACK45, BD Pharmingen,
San Diego, CA) for 30 min at 4 C. RBL-1 and RBL-2H3 cells were
stained with mouse anti-rat FceRI antibody (clone BC4, BD Pharm-
ingen), followed by FITC-labeled anti-mouse IgG. For lamina propria
mononuclear cells (LPMCs), cells were incubated with FcR blocking
reagentmouse (MACS, Auburn, CA) for 5 min and stainedwith FITC-
labeled anti-mouse IgE and PE-labeled anti-mouse CD117. Propidi-
um Iodide (Sigma) and Viaprobe (BD Pharmingen) were used to dis-
criminate between dead and live cells. Flow cytometric analysis was
performed using FACSCalibur and Cell QuestPro software version
6.0 (BD Biosciences, Franklin Lakes, NJ). Percent inhibition of FceRI
expression was determined using mean ﬂuorescence intensity
(MFI), with vehicle-treated cells as the baseline for all comparisons.2.3. Intracellular calcium measurements
Sensitized mBMMCs with mouse anti-dinitrophenyl (DNP) IgE
antibodies were loaded with 5 lM Fura-2 AM (Dojindo, Kuma-
moto, Japan) in loading buffer (118 mM NaCl, 4.7 mM KCl, 1 mM
Na2HPO4, 1.13 mM MgCl2, 10 mM HEPES, 5.5 mM D-glucose,
100 mM L-glutamine, 1.3 mM CaCl2, 2% MEM non-essential amino
acids, 0.2% BSA) for 30 min, washed once, resuspended in 1.3 mL of
loading buffer and warmed to 37 C in the cuvette. Fluorescence
was measured at 340 and 380 nm using a model F-4500 ﬂuores-
cence spectrophotometer intracellular Ca2+ measurement system
(Hitachi, Tokyo, Japan), and the background-corrected 340:380 ra-
tio was calibrated.
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Fig. 4. PGG affects the mRNA expression level of FceRI subunits. mBMMCs were cultured with 100 lM PGG and vehicle for 24 h and mRNA levels of a, b, and c subunits of
FceRI were analyzed by real-time PCR as described in the material and methods. Relative mRNA levels of FceRI subunits were normalized to GAPDH expression. Data
represent mean ± S.D. values of three experiments. **P < 0.01 compared with vehicle-treated cells.
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Total RNA was isolated from mBMMCs using RNeasy Plus Micro
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Reverse transcription was performed using Prime-
Script RT reagent kit (Takara Bio, Shiga, Japan) and random prim-
ers. Quantitative real-time PCR was performed using SYBR
Premix Ex Taq (Takara Bio) and Mx3000p system (Stratagene, La
Jolla, California, USA). The following primer pairs were used:
FceRIa, forward 50-TGAATGACAGTGGCACCTACCA-30 and reverse
50-CAGAATCGCCACCAACAATG-30, FceRIb, forward 50-AGTGCTG-
TGTTGTTCACTAT-30 and reverse 50-TCCAACTCACTGTAAATTGG-30,
FceRIc, forward 50-ATATCCTGGATGCTGTCCTG-30 and reverse
50-TCTCATATGTCTCCTGGCTC-30 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), forward 50-TGACCACAGTCCATGCCATC-
30 and reverse 50-GACGGACACATTGGGGGTAG-30. Target mRNA
was normalized to GAPDH mRNA as an internal control in each
sample. Results were expressed as the ratio relative to the vehi-
cle-treated cells.
2.5. Allergic diarrhea induction in a murine food-allergy model, LPMC
isolation, histological analysis, and measurement of plasma histamine
level
Five-week-oldmale BALB/cmicewere housed in the experimen-
tal animal facility at University of Toyama. Intestinal anaphylaxis
was induced as previously described [5]. For the treatment with
PGG (Toronto Research Chemicals Inc., Ontario, Canada) in the
food-allergy model, PGG was orally administered to mice everyday
throughout the period of oral ovalbumin (OVA) administration. All
animal care and experiments were approved by the Animal Exper-
iment Committee in University of Toyama (Authorization No. INM-
13). LPMC were isolated by the procedure described previously
[11]. For histological analysis, the proximal colon was excised one
hour after the oral OVA challenge, and stained with antibodies
against mouse mast cell protease (mMCP)-1 by the procedure de-
scribed previously [5]. The jejunumwas stained with toluidine blue
at pH 0.5 for 48 h. The plasma sampleswere obtained one hour after
the oral OVA challenge, and the histamine levels were measured
using ELISA (SPI Bio, Paris, France).
2.6. Statistical analysis
Statistical comparisons were made using one-way ANOVA fol-
lowed by Bonferroni/Dunn post-hoc tests for multiple compari-
sons. In some ﬁgures, means were compared with a hypothetical
value of 100 using a one-sample t-test. Probability values (P) of
<0.05 were considered as statistically signiﬁcant.3. Results and discussion
3.1. Kakkonto inhibits mBMMC degranulation and surface expression
of FceRI
mBMMCs were treated with serial concentrations of Kakkonto
(Tsumura Co., Tokyo, Japan) during pre-incubation (24 h) and sen-
sitization with IgE anti-DNP (6 h), and the extent of degranulation
was assessed by b-hexosaminidase release (Fig. 1A). Kakkonto
(P0.5 mg/mL) inhibited the degranulation of mBMMCs in a dose-
dependent manner.
As assessed by ﬂow cytometry to detect FceRI and c-kit, we
found that the levels of FceRI expression on the surface of
mBMMCs were greatly inhibited upon incubation of the cells
in vitro with Kakkonto (2 mg/mL). Interestingly, the surface
expression levels of c-kit were not changed by treatment with
Kakkonto (Fig. 1B).
3.2. Paeoniae Radix inhibits mBMMC degranulation and surface
expression of FceRI
Kakkonto is composed of seven medicinal herbs: Puerariae Ra-
dix, Cinnamomi Cortex, Zizyphi Fructus, Paeoniae Radix, Ephedrae
Herba, Zingiberis Rhizoma, and Glycyrrhizae Radix. To determine
which medicinal herb has an inhibitory effect on degranulation
of mBMMCs, we used various herbal medicines (Tsumura Co.)
listed in Table 1, in which the composition of medicinal herbs
are similar to Kakkonto, and their effects on mBMMCs were tested.
Among them, every medicine which showed the inhibitory effect
on degranulation contains Paeoniae Radix. We then tested the ef-
fect of Paeoniae Radix (Tsumura Co.) on mBMMCs. As expected, it
was found that treatment with Paeoniae Radix extract decreased
the expression levels of FceRI on the cell surface of mBMMCs,
and that P0.5 mg/mL of Paeoniae Radix signiﬁcantly inhibited the
degranulation of mBMMCs (Fig. 1C and D).
3.3. PGG inhibits surface expression of FceRI and function on mBMMCs
in vitro
We investigated inhibitory effects of major constituents of
Paeoniae Radix, paeoniﬂorin (Nacalai Tesque, Kyoto, Japan), albiﬂo-
rin (Wako Pure Chemical Industries, Osaka, Japan), oxypaeoniﬂorin
(a gift from Tsumura Co.), paeonol (Wako), and PGG, on the FceRI
surface expression. As shown in Fig. 2A, only PGG drastically de-
creased the FceRI surface expression on mBMMCs, whereas the
other four components did not. The concentration-dependency of
PGG on the surface expression of FceRI and DNP-BSA-induced
degranulation were tested (Fig. 2B and C). PGG at a concentration
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Fig. 5. PGG suppresses the development of allergic diarrhea. (A) Allergic diarrhea induction in mock- and PGG-treated groups was compared. PGG (5 mg/kg) was orally
administered during induction of allergic diarrhea by OVA oral challenge as described in Material and Methods. Similar results were obtained from three independent
experiments. Mock, n = 10; 5 mg/kg PGG, n = 20. (B) Mononuclear cells from large intestinal lamina propria were isolated from normal, mock-treated, and PGG-treated mice
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effect on FceRI was consistently found in rat mast cell lines RBL-
1 and RBL-2H3 (Fig. 2D), making it unlikely that the present dataare related to culture artifacts or species differences. PGG
(P32 lM) inhibited the degranulation of mBMMCs (Fig. 2C). In
contrast, 100 lM PGG failed to affect calcium ionophore A23187
N. Kageyama-Yahara et al. / FEBS Letters 584 (2010) 111–118 117(Sigma)-induced degranulation of mBMMCs (Fig. 2E). These results
suggested that FceRI-dependent activation, but not FceRI-indepen-
dent activation of mast cells is inhibited by PGG treatment.
Interestingly, PGG down-regulated surface expression of FceRI
on mBMMCs without affecting the level of c-kit surface expression
(Fig. 2B). Although IL-4, IL-10, and TGF-b1 have been shown to
down-regulate FceRI surface expression in mast cells [7], these
cytokines are also known as inhibitors of c-kit expression [12,13].
c-kit has been shown to be not only essential for mast cell growth
and differentiation but also to act on multipotential stem and pro-
genitor cells, megakaryocytes, and a subset of lymphoid progeni-
tors [14]. Therefore, PGG has the therapeutic advantage of
minimizing side effects, because PGG had no inﬂuence on the sur-
face expression of c-kit.
In the present evaluation system, none of tranilast (Sigma),
ketotifen (Sigma), and cromolyn (Sigma) that inhibit the release
of chemical mediators from connective-tissue mast cells in vitro
[15], exerted inhibitory effects on the degranulation of mBMMCs
(Fig. 3A), suggesting that PGG has a stronger inhibitory effect on
mucosal mast cells than these anti-allergic drugs.
PGG contains one glucose molecule and is esteriﬁed with ﬁve
gallic acids on ﬁve hydroxyl groups of the glucose. The effect of
1,3,6-tri-O-galloyl-b-D-glucose (TGG, ChromaDex, Irvine, CA) was
lower than that of PGG, and gallic acid (GA, Nacalai Tesque) exhib-
ited no detectable change in FceRI surface expression and in
degranulation (Fig. 3B and C), suggesting that the gallate structure
of PGG, not the gallic acid moieties, may play a critical role in the
down-regulation of FceRI.
The cross-linking of FceRI by antigen triggers mast cell activa-
tion, leading to the elevation intracellular of concentration of
Ca2+ ([Ca2+]i) prior to the exocytosis of granules [16]. To examine
the effect of PGG on [Ca2+]i elevation in mast cells, mBMMCs were
treated with 32 lM PGG for 24 h and [Ca2+]i was monitored using
Fura-2 AM. As shown in Fig. 3D, PGG treatment inhibited the
increase of [Ca2+]i triggered by DNP-BSA.
3.4. PGG inhibits mRNA expression of FceRI subunits
FceRI is composed of three subunits: a, b, and c. To examine
whether the mRNA expression level of FceRI is altered by treat-
ment with PGG, mBMMCs were treated with 100 lM PGG or vehi-
cle for 24 h, and mRNA levels of FceRI subunits were examined by
quantitative real-time PCR. As shown in Fig. 4, PGG decreased
mRNA expression of FceRIa, b, and c subunits. It has been reported
that PGG inhibits gene expression of IL-8 in human monocytic
U937 cells [17] and that of IL-1b, IL-6, and tumor necrosis factor-
a in human mast cells [18]. Although the precise mechanisms re-
main to be determined, PGGmay also be a potent inhibitor of FceRI
gene expression.
3.5. PGG down-regulates the FceRI expression of mast cells in vivo and
prevents antigen-speciﬁc allergic diarrhea
We next investigated whether PGG affected the FceRI surface
expression of mucosal mast cells in an in vivo allergic model. As
shown in Fig. 5A, the induction of allergic diarrhea was partially
prevented in PGG-treated mice. To examine whether PGG actually
down-regulated FceRI surface expression in mucosal mast cells
in vivo, mononuclear cells were isolated from the large intestinal
lamina propria and IgE-bound c-kit+ mast cells were determined
by ﬂow cytometry (Fig. 5B). The number of mast cells was dramat-
ically increased in the mock-treated food-allergy mice compared
with normal mice. This result was consistent with our previous re-
sult as observed by immunohistochemical analysis [5]. PGG treat-
ment reduced the surface-binding of IgE, suggesting that PGG
down-regulated the surface expression level of FceRI even in thein vivo food-allergy model. It has been shown that FceRI surface
expression is up-regulated by IgE both in vivo and in vitro
[19,20]. In this model, however, Kakkonto treatment did not alter
the level of IgE in the plasma [5], suggesting that the down-regula-
tion of FceRI surface expression on mast cells is not due to reduc-
tion of IgE level in the plasma.
To examine whether PGG indeed inhibited the mast cell activity
in vivo, we stained the mice colon and the jejunum using antibody
against mouse mast cell protease-1 (mMCP-1), a marker of mouse
mucosal mast cells (Fig. 5C), and toluidine blue (Fig. 5D), respec-
tively. Consistent with our previous report [5], the number of mast
cells was dramatically increased in the intestine of the food-allergy
mice compared to that of normal mice. PGG treatment greatly de-
creased the number of inﬁltrating mast cells (Fig. 5C and D), sug-
gesting that the allergic symptoms were ameliorated by the
administration of PGG. We could not see the difference in hista-
mine levels in plasma among normal, mock-treated, and PGG-trea-
ted mice (Fig. 5E). This result is convincing because it is reported
that the histamine content is much lower in mucosal mast cells
than in connective-tissue mast cells [4], and that a combination
of histamine H1 and H2 receptor antagonists cannot alleviate aller-
gic diarrhea in another murine food-allergy model resembling the
model we used in the present study [23].4. Conclusion
In summary, our results demonstrate that PGG down-regulated
FceRI surface expression in mast cells both in vitro and in vivo, and
thereby inhibited the degranulation of these cells in response to
IgE-dependent activation. Omalizumab therapy, a clinically effec-
tive monoclonal anti-IgE capable of preventing IgE binding to
FceRI, reduced surface IgE receptor expression [21,22]. Our ﬁnd-
ings presented herein provide further support for the notion that
down-regulation of FceRI is functionally signiﬁcant, as it dimin-
ishes the allergic reaction. The inhibitory effects of PGG on FceRI
surface expression may offer a new potential therapeutic approach
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